Efficacy and safety of neoadjuvant chemotherapy versus neoadjuvant concurrent radiochemotherapy for resectable esophageal squamous cell carcinoma: a meta-analysis
10.3760/cma.j.cn112434-20200619-00300
- VernacularTitle:可切除食管鳞癌新辅助化疗对比新辅助同步放化疗的meta分析
- Author:
Xue ZHAO
1
;
Sheng WANG
;
Hao ZHAN
;
Yiqing ZHANG
;
Kaiguo SUN
;
Zhaohui QIN
;
Yuanhu YAO
Author Information
1. 徐州医科大学附属医院肿瘤放射治疗科 221002
- Keywords:
Esophageal neoplasms/neoadjuvant radiochemotherapy;
Esophageal neoplasms/neoadjuvant chemotherapy;
Prognosis;
Meta-analysis
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2021;37(9):526-532
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematic review the clinical efficacy and safety of neoadjuvant chemotherapy and neoadjuvant concurrent chemoradiotherapy for resectable esophageal squamous cell carcinoma.Methods:Literature search was performed from Web of Science, Pubmed, Cochrane Library, Embase, CBM, Wanfang Data, CNKI and Chongqing VIP. The clinical controlled studies of neoadjuvant chemotherapy versus neoadjuvant concurrent chemoradiation in the treatment of resectable esophageal squamous cell carcinoma was searched. Relevant outcome indicators were analyzed by Revman 5.3 statistical software.Results:Nine studies were included, with a total of 1, 369 patients. Compared with the neoadjuvant chemoradiotherapy, the neoadjuvant chemotherapy had lower overall survival rates at 3 and 5 years( OR=0.68, 95% CI: 0.53-0.86, P<0.05; OR=0.51, 95% CI: 0.34-0.77, P<0.05) , lower pathological complete remission rate( OR=0.28, 95% CI: 0.18-0.45, P<0.05)and R0 resection rate( OR=0.39, 95% CI: 0.22-0.68, P<0.05), The total postoperative complication rate is similar( OR=1.07, 95% CI: 0.75-1.51, P>0.05). Conclusion:Neoadjuvant concurrent radiochemotherapy maybe superior to neoadjuvant chemotherapy among patients with resectable esophageal squamous cell carcinoma.
